BiotechTube

Fidaxomicin

Pre-clinicalWithdrawn
1 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Clostridium Difficile Infection (CDI)

Conditions

Clostridium Difficile Infection (CDI)

Trial Timeline

Aug 1, 2019 → May 1, 2023

NCT ID
NCT04070352

About Fidaxomicin

Fidaxomicin is a pre-clinical stage product being developed by Merck for Clostridium Difficile Infection (CDI). The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04070352. Target conditions include Clostridium Difficile Infection (CDI).

What happened to similar drugs?

9 of 20 similar drugs in Clostridium Difficile Infection (CDI) were approved

Approved (9) Terminated (5) Active (11)
✅Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
✅Fidaxomicin + VancomycinAstellas PharmaApproved
✅Fidaxomicin + VancomycinMerckApproved
✅Vancomycin + FidaxomicinMerckApproved
✅bezlotoxumab + Vancomycin OralMerckApproved
✅Fidaxomicin 200 mg + Placebo + VancomycinMerckApproved
✅BezlotoxumabMerckApproved

Hype Score Breakdown

Clinical
3
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04070352Pre-clinicalWithdrawn
NCT01591863Phase 2Completed

Competing Products

20 competing products in Clostridium Difficile Infection (CDI)

See all competitors
ProductCompanyStageHype Score
Metronidazole + Metronidazole-DRF1 + Metronidazole-DRF2Dr. Reddy's LaboratoriesPhase 2
32
Fidaxomicin + Vancomycin + PlaceboAstellas PharmaApproved
35
Fidaxomicin + Treatment for CDI other than fidaxomicin TypeAstellas PharmaPre-clinical
26
OPT-80 + vancomycinAstellas PharmaPhase 3
40
Fidaxomicin oral suspension + Fidaxomicin tablets + Vancomycin oral liquid + Vancomycin capsulesAstellas PharmaPhase 3
40
Fidaxomicin + VancomycinAstellas PharmaApproved
43
Fidaxomicin + VancomycinMerckApproved
43
fidaxomicin + PlaceboMerckPhase 3
40
Surotomycin + PlaceboMerckPhase 1
29
CB-183,315 + Placebo + VancomycinMerckPhase 2
35
Surotomycin + PlaceboMerckPhase 1
29
MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Vancomycin + FidaxomicinMerckApproved
43
Bezlotoxumab + Standard CDI treatmentMerckPre-clinical
26
MK-3415 + MK-6072 + MK-3415A + Placebo + SOCMerckPhase 3
40
Fidaxomicin + Vancomycin + Matching Placebo to FidaxomicinMerckPhase 3
40
bezlotoxumab + Vancomycin OralMerckApproved
43
Bezlotoxumab + Placebo + Antibacterial drug treatment (ABD)MerckPhase 3
40
Bezlotoxumab Injection [Zinplava]MerckPre-clinical
26
PAR-101/OPT-80 + VancomycinMerckPhase 3
40